Eli Lilly Stock Surges on Blockbuster Earnings Driven by Mounjaro and Zepbound

Eli Lilly`s stock surged due to exceeding profit and sales expectations, primarily driven by the success of its diabetes and weight-loss drugs Mounjaro and Zepbound. While the company raised its sales forecast and anticipates continued growth, its high stock price relative to earnings raises concerns about long-term value. Analysts suggest that while the stock remains attractive for now, investors might consider selling in the future as growth rates are projected to decline.